세계의 잠복 결핵 검사 시장 예측(-2029년) : 검사 유형별, 용도별, 최종사용자별, 지역별

The latent TB testing market will rise in value from estimated USD 582.5 million in 2024 to USD 773.4 million in 2029, at a CAGR of 5.8% over the forecast period. Increased funding and grants for TB control programs across the globe have emerged as an important growth factor in the latent TB testing market. Substantial funding is now being committed by governments and international bodies, including WHO and the Global Fund, to address the increasing burden of TB, especially in terms of early detection and prevention. These funds are being channeled into increasing access to diagnostic facilities, especially in high-burden regions where the healthcare infrastructure is generally weak. The availability of funds also encourages the training of healthcare professionals who work with a patient to accurately diagnose and properly manage cases of latent TB. Apart from that, research grants and international collaborations are also enabling TB testing integration into routine healthcare services. Thus, this growing funding is rendering latent TB tests available and enhancing the efforts to control TB globally. This, in turn, is fuelling the growth of the global latent TB testing market.

"Interferon gamma release assay (IGRA) segment is expected to have the fastest growth rate in the latent TB testing market, by test type, during the forecast period."

The latent TB testing market is segmented into tuberculin skin test (TST) and interferon gamma release assay (IGRA), based on test type. Interferon gamma release assay (IGRA) tests are projected to account for the highest CAGR during the forecast period. One major driving factor is its higher accuracy than conventional tuberculin skin tests (TST); IGRA tests do not suffer from interference by prior BCG vaccination, which can cause false positives for TST. Thus, IGRA is preferred in populations that have high BCG vaccination coverage. Furthermore, IGRA tends to offer faster and more consistent results, meaning that patients require fewer visits, enhancing overall efficiency in testing. Growing penetration of these tests in high-risk populations, such as patients who are immunocompromised and health care workers, continue to support increased demand. Favourable regulatory approvals and recommendations by various international health bodies, including the WHO, have also helped increase their adoption. Along with such factors, rising funding for research in TB and advancements in diagnostics are also driving the high growth of the IGRA test segment in the latent TB testing market.

"Household contacts with pulmonary TB segment accounted for the highest growth rate in the latent TB testing market, by application, during the forecast period."

Based on application, the latent TB testing market is bifurcated into household contacts (HHC) with pulmonary tuberculosis (TB)/household contacts (HHC) of tuberculosis (TB) patients, people living with HIV, and other applications. The household contacts with pulmonary TB application segment is expected to have the highest CAGR during the forecast period. Individuals in close contact with a TB patient have a much higher probability of becoming infected with latent TB, which is the reason why regular screenings are crucial in being able to diagnose the illness early and intervene by taking preventive measures. Increasing recognition of the critical role that latent TB testing plays among high-risk groups by healthcare providers and public health agencies also drives the need for accurate latent TB diagnostics. In addition, screening of contacts across the households by the governments and TB control programs in efforts to curb latent infections from becoming active TB is further driving growth in the market segment. Collectively, all these factors are contributing to the fast growth of this application within the latent TB testing market.

"Asia Pacific: The fastest-growing region in latent TB testing market."

The worldwide market for latent TB testing is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region bears a high burden of tuberculosis, such as in India and China, which record a high incidence rate and thereby drive the need for essential latent TB screening and management. Growth in government and international organization funding and campaigns against TB has also led to better access to diagnostics and healthcare infrastructure in Asia Pacific. Awareness among the communities and among healthcare workers regarding the need for early detection of latent TB has also been significantly increasing the demand for further testing. Another major growth driver of this segment in the latent TB testing market is the increasing healthcare expenditure, along with supportive regulatory frameworks. All these factors propel increased growth of the latent TB testing market in the Asia Pacific region.

The break-up of the profile of primary participants in the latent TB testing market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), Endo, Inc. (US), bioMerieux (France), SD Biosensor, INC. (South Korea), Lionex GmbH (Germany), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), ARKRAY, Inc. (Japan), Zhi Fei Biological (China), AID Autoimmun Diagnostika GmbH (Germany), Boditech Med Inc. (South Korea), Bioneovan Co., Ltd (China), and Biopanda Reagents Ltd (UK).

Research Coverage:

This research report categorizes the latent TB testing market by test type (tuberculin skin test (TST) and interferon gamma release assay (IGRA)), by application (household contacts with pulmonary TB, people living with HIV, and other applications), by end user (diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the latent TB testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the latent TB testing market. Competitive analysis of upcoming startups in the latent TB testing market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall latent TB testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising incidence of latent tuberculosis, widespread use of BCG vaccine, and increased funding and grants for TB control programs), opportunities (Growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (changing regulatory landscape and operational barriers and labor shortage) influencing the growth of the latent TB testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the latent TB testing market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the latent TB testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the latent TB testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like QIAGEN (Netherlands), Revvity (US), Beijing Wantai Biopharmaceutical Co., Ltd. (China), Sanofi (France), and Endo, Inc. (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Key data from secondary sources
    • 2.1.1.3 Objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of primaries
      • 2.1.2.4.1 Breakdown of primary interviews: supply & demand-side
      • 2.1.2.4.2 Breakdown of primary interviews: by company type, designation, and region
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Company revenue estimation approach
    • 2.2.1.2 Presentations of companies and primary interviews
    • 2.2.1.3 Growth forecast
    • 2.2.1.4 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 ASSUMPTIONS
  • 2.5.1 STUDY ASSUMPTIONS
  • 2.5.2 GROWTH RATE ASSUMPTIONS
• 2.6 LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 LATENT TB TESTING MARKET OVERVIEW
• 4.2 LATENT TB TESTING MARKET, BY TEST TYPE, 2024 VS. 2029
• 4.3 LATENT TB TESTING MARKET, BY APPLICATION, 2024 VS. 2029
• 4.4 LATENT TB TESTING MARKET, BY END USER, 2024 VS. 2029
• 4.5 LATENT TB TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising incidence of latent tuberculosis
    • 5.2.1.2 Widespread use of BCG vaccine
    • 5.2.1.3 Increased funding and grants for TB control programs
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursement scenario
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Changing regulatory landscape
    • 5.2.4.2 Operational barriers and labor shortage
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE SELLING PRICE, BY PRODUCT
  • 5.3.2 INDICATIVE PRICE OF IGRA TESTS, BY REGION
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA
  • 5.7.2 EXPORT DATA
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 KEY BUYING CRITERIA
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY LANDSCAPE
    • 5.11.1.1 North America
      • 5.11.1.1.1 US
      • 5.11.1.1.2 Canada
    • 5.11.1.2 Europe
      • 5.11.1.2.1 Germany
      • 5.11.1.2.2 UK
      • 5.11.1.2.3 France
      • 5.11.1.2.4 Italy
      • 5.11.1.2.5 Spain
    • 5.11.1.3 Asia Pacific
      • 5.11.1.3.1 China
      • 5.11.1.3.2 Japan
      • 5.11.1.3.3 India
      • 5.11.1.3.4 Australia
      • 5.11.1.3.5 South Korea
      • 5.11.1.3.6 Singapore
    • 5.11.1.4 Latin America
      • 5.11.1.4.1 Brazil
      • 5.11.1.4.2 Mexico
    • 5.11.1.5 Middle East
      • 5.11.1.5.1 Africa
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.11.2.1 North America
    • 5.11.2.2 Europe
    • 5.11.2.3 Asia Pacific
    • 5.11.2.4 Latin America
    • 5.11.2.5 Rest of the world
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGIES
    • 5.12.1.1 Tuberculin skin test
  • 5.12.2 COMPLEMENTARY TECHNOLOGIES
    • 5.12.2.1 Interferon gamma released assay
• 5.13 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: EXPLORING CYTOKINE USAGE IN MONITORING LTBI TREATMENT
  • 5.16.2 CASE STUDY 2: ASSESSING DIAGNOSTIC ACCURACY OF ESAT6-CFP10 (EC) SKIN TEST FOR LTBI DETECTION
  • 5.16.3 CASE STUDY 3: EVALUATING MTB-SPECIFIC CYTOKINE RESPONSES FOR ENHANCED LTBI DETECTION IN HEU INFANTS
• 5.17 LATENT TB CONTROL STRATEGIES IN MAJOR COUNTRIES
  • 5.17.1 NORTH AMERICA
    • 5.17.1.1 US
    • 5.17.1.2 Canada
  • 5.17.2 EUROPE
    • 5.17.2.1 Germany
    • 5.17.2.2 UK
  • 5.17.3 ASIA PACIFIC
    • 5.17.3.1 Japan
    • 5.17.3.2 China
    • 5.17.3.3 India
    • 5.17.3.4 Singapore
• 5.18 IMPACT OF AI ON LATENT TB TESTING MARKET
  • 5.18.1 KEY USE CASES

6 LATENT TB TESTING MARKET, BY TEST TYPE

• 6.1 INTRODUCTION
• 6.2 IGRA
  • 6.2.1 HIGHER SPECIFICITY AND ACCURACY TO BOOST MARKET SEGMENT
• 6.3 TST
  • 6.3.1 COST-EFFECTIVENESS TO PROPEL MARKET GROWTH

7 LATENT TB TESTING MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 PEOPLE LIVING WITH HIV
  • 7.2.1 RISING RATES OF TB-HIV COINFECTION TO PROPEL GROWTH
• 7.3 HOUSEHOLD CONTACTS (HHC) WITH PULMONARY TUBERCULOSIS (TB)/ HOUSEHOLD CONTACTS (HHC) OF TUBERCULOSIS (TB) PATIENTS
  • 7.3.1 NEED FOR ROUTINE SCREENING FOR HOUSEHOLD CONTACTS TO BOOST SEGMENT
• 7.4 OTHER APPLICATIONS

8 LATENT TB TESTING MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 DIAGNOSTIC LABORATORIES
  • 8.2.1 WELL-DEVELOPED INFRASTRUCTURE AND CAPABILITIES TO SUPPORT DEMAND FOR TESTING METHODS
• 8.3 HOSPITALS & CLINICS
  • 8.3.1 GROWING NUMBER OF HOSPITALS AND GOVERNMENT INVESTMENTS IN HEALTHCARE TO BOOST SEGMENT
• 8.4 ACADEMIC & RESEARCH INSTITUTES
  • 8.4.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS TO SUPPORT MARKET GROWTH
• 8.5 OTHER END USERS

9 LATENT TB TESTING MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 9.2.2 US
    • 9.2.2.1 US to dominate North American latent TB testing market
  • 9.2.3 CANADA
    • 9.2.3.1 Improved screening and treatment for latent TB to drive market
• 9.3 ASIA PACIFIC
  • 9.3.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 9.3.2 CHINA
    • 9.3.2.1 Growing public access to modern healthcare to fuel market growth
  • 9.3.3 JAPAN
    • 9.3.3.1 Presence of universal healthcare reimbursement policy to drive market
  • 9.3.4 INDIA
    • 9.3.4.1 High TB burden and growing government initiatives to drive demand for latent TB screening
  • 9.3.5 SOUTH KOREA
    • 9.3.5.1 Rising healthcare spending in innovative diagnostic technologies to support market growth
  • 9.3.6 AUSTRALIA
    • 9.3.6.1 Diverse immigrant population to fuel demand for latent TB screening
  • 9.3.7 SINGAPORE
    • 9.3.7.1 Enhanced healthcare infrastructure to propel market growth
  • 9.3.8 REST OF ASIA PACIFIC
• 9.4 EUROPE
  • 9.4.1 EUROPE: MACROECONOMIC OUTLOOK
  • 9.4.2 UK
    • 9.4.2.1 Growing number of diagnostic centers to fuel market
  • 9.4.3 FRANCE
    • 9.4.3.1 Presence of robust healthcare system to augment market growth
  • 9.4.4 GERMANY
    • 9.4.4.1 Higher healthcare spending and favorable government policies to favor market growth
  • 9.4.5 SPAIN
    • 9.4.5.1 Improving healthcare infrastructure to drive demand
  • 9.4.6 ITALY
    • 9.4.6.1 Improved quality of medical care to spur market growth
  • 9.4.7 BELGIUM
    • 9.4.7.1 Targeted screening for high-risk groups to fuel demand
  • 9.4.8 SWEDEN
    • 9.4.8.1 Growing immigrant population from high-prevalence regions to propel demand
  • 9.4.9 DENMARK
    • 9.4.9.1 Importance of latent TB testing in public health strategy to support market growth
  • 9.4.10 REST OF EUROPE
• 9.5 LATIN AMERICA
  • 9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 9.5.2 BRAZIL
    • 9.5.2.1 Developed public health systems and improving healthcare infrastructure to favor market growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Modernization of healthcare infrastructure to augment market growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 9.6.2 SOUTH AFRICA
    • 9.6.2.1 Rising government initiatives for TB screening to augment market growth
  • 9.6.3 SAUDI ARABIA
    • 9.6.3.1 Enhancements in healthcare infrastructure to support market growth
  • 9.6.4 UAE
    • 9.6.4.1 UAE ranks among the world's leading countries with low TB rates
  • 9.6.5 KUWAIT
    • 9.6.5.1 Expansion of healthcare infrastructure to augment market growth
  • 9.6.6 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LATENT TB TESTING MARKET
• 10.3 REVENUE SHARE ANALYSIS
• 10.4 MARKET SHARE ANALYSIS
  • 10.4.1 MARKET SHARE ANALYSIS, BY REGION
    • 10.4.1.1 North America
    • 10.4.1.2 Europe
    • 10.4.1.3 Asia Pacific
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Test type footprint
    • 10.5.5.3 Application footprint
    • 10.5.5.4 Region footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
• 10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.7.1 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023
• 10.8 VALUATION & FINANCIAL METRICS
• 10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 10.9.1 QIAGEN
  • 10.9.2 REVVITY
  • 10.9.3 BIOMERIEUX
• 10.10 COMPETITIVE SCENARIO
  • 10.10.1 PRODUCT LAUNCHES
  • 10.10.2 DEALS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 QIAGEN
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product launches & approvals
      • 11.1.1.3.2 Deals
      • 11.1.1.3.3 Expansions
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 REVVITY (OXFORD IMMUNOTEC)
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches & approvals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 BEIJING WANTAI BIOPHARMACEUTICAL CO., LTD.
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 MnM view
      • 11.1.3.3.1 Right to win
      • 11.1.3.3.2 Strategic choices
      • 11.1.3.3.3 Weaknesses & competitive threats
  • 11.1.4 SANOFI
    • 11.1.4.1 Business overview
    • 11.1.4.2 MnM view
      • 11.1.4.2.1 Right to win
      • 11.1.4.2.2 Strategic choices
      • 11.1.4.2.3 Weaknesses & competitive threats
  • 11.1.5 ENDO, INC.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 MnM view
      • 11.1.5.3.1 Key strengths
      • 11.1.5.3.2 Strategic choices
      • 11.1.5.3.3 Weaknesses and competitive threats
  • 11.1.6 BIOMERIEUX
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product approvals
  • 11.1.7 SD BIOSENSOR, INC.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Deals
  • 11.1.8 LIONEX GMBH
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
  • 11.1.9 SERUM INSTITUTE OF INDIA PVT. LTD.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
  • 11.1.10 ARKRAY, INC.
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Expansions
• 11.2 OTHER PLAYERS
  • 11.2.1 ZHI FEI BIOLOGICAL
  • 11.2.2 AID AUTOIMMUN DIAGNOSTIKA GMBH
  • 11.2.3 BODITECH MED INC.
  • 11.2.4 BIONEOVAN CO., LTD.
  • 11.2.5 BIOPANDA REAGENTS LTD.

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS